Literature DB >> 17689290

Interleukin-10 and the pathogenesis of human visceral leishmaniasis.

Susanne Nylén1, David Sacks.   

Abstract

The mechanisms underlying the failure to control the growth and systemic spread of Leishmania parasites in human visceral leishmaniasis (VL) are not well understood. Although the absence of antigen-specific Th1 responses in the peripheral blood mononuclear cells from VL patients is thought to be causally related to disease progression, the finding that these patients also express elevated interferon-gamma mRNA in lesional tissue, as well as elevated serum levels of proinflammatory cytokines, suggests that their immunological defect cannot be explained simply by immune tolerance or Th2 polarization. As a possible homeostatic mechanism to control persistent infection-induced inflammation, elevated levels of the regulatory cytokine interleukin (IL)-10 have been reported repeatedly in clinical studies of VL. Here, we review the studies with relevance to immune responses in human VL and highlight the central role that IL-10 might have in the pathogenesis of VL and as a target for immune-based therapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17689290     DOI: 10.1016/j.it.2007.07.004

Source DB:  PubMed          Journal:  Trends Immunol        ISSN: 1471-4906            Impact factor:   16.687


  166 in total

1.  Systemic inflammatory responses in progressing periodontitis during pregnancy in a baboon model.

Authors:  J L Ebersole; M J Steffen; S C Holt; L Kesavalu; L Chu; D Cappelli
Journal:  Clin Exp Immunol       Date:  2010-12       Impact factor: 4.330

2.  Characterization of regulatory T cell (Treg) function in patients infected with Leishmania braziliensis.

Authors:  Diego L Costa; Luiz H Guimarães; Thiago M Cardoso; Adriano Queiroz; Ednaldo Lago; Ana M Roselino; Olívia Bacellar; Edgar M Carvalho; João S Silva
Journal:  Hum Immunol       Date:  2013-08-28       Impact factor: 2.850

3.  Reassessment of immune correlates in human visceral leishmaniasis as defined by cytokine release in whole blood.

Authors:  Om Prakash Singh; Kamlesh Gidwani; Rajiv Kumar; Susanne Nylén; Stephen L Jones; Marleen Boelaert; David Sacks; Shyam Sundar
Journal:  Clin Vaccine Immunol       Date:  2012-04-25

4.  Is the IL-10 -819 polymorphism associated with visceral leishmaniasis?

Authors:  Mehrdad Hajilooi; Kosro Sardarian; Maryam Dadmanesh; Mohamad Matini; Pegah Lotfi; Ahad Bazmani; Mohammad Amin Tabatabaiefar; Mohammad Kazemi Arababadi; Mohammad Momeni
Journal:  Inflammation       Date:  2013-12       Impact factor: 4.092

5.  HLA-DR Class II expression on myeloid and lymphoid cells in relation to HLA-DRB1 as a genetic risk factor for visceral leishmaniasis.

Authors:  Bhawana Singh; Michaela Fakiola; Medhavi Sudarshan; Joyce Oommen; Siddharth Sankar Singh; Shyam Sundar; Jenefer M Blackwell
Journal:  Immunology       Date:  2018-11-22       Impact factor: 7.397

Review 6.  Kinetoplastids: related protozoan pathogens, different diseases.

Authors:  Ken Stuart; Reto Brun; Simon Croft; Alan Fairlamb; Ricardo E Gürtler; Jim McKerrow; Steve Reed; Rick Tarleton
Journal:  J Clin Invest       Date:  2008-04       Impact factor: 14.808

7.  Influence of genetic variants of gamma interferon, interleukins 10 and 12 on Visceral Leishmaniasis in an endemic area, Iran.

Authors:  Mehdi Kalani; Maral Choopanizadeh; Manoochehr Rasouli
Journal:  Pathog Glob Health       Date:  2019-01-15       Impact factor: 2.894

Review 8.  Adaptive immunity to the obligate intracellular pathogen Coxiella burnetii.

Authors:  Jeffrey G Shannon; Robert A Heinzen
Journal:  Immunol Res       Date:  2009       Impact factor: 2.829

Review 9.  Cell type-specific regulation of IL-10 expression in inflammation and disease.

Authors:  Christian M Hedrich; Jay H Bream
Journal:  Immunol Res       Date:  2010-07       Impact factor: 2.829

10.  Hyperlipidemia offers protection against Leishmania donovani infection: role of membrane cholesterol.

Authors:  June Ghosh; Shantanabha Das; Rajan Guha; Debopam Ghosh; Kshudiram Naskar; Anjan Das; Syamal Roy
Journal:  J Lipid Res       Date:  2012-10-10       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.